ISSN 1662-4009 (online)

ey0021.12-15 | Lipid Metabolism | ESPEYB21

12.15. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries

MD Reijman , TR Tromp , BA Hutten , GK Hovingh , DJ Blom , AL Catapano , M Cuchel , EJ Dann , A Gallo , LC Hudgins , FJ Raal , KK Ray , F Sadiq , H Soran , JW Groothoff , A Wiegman , DM Kusters

Brief Summary: Data from two large registries of children with homozygous familial hypercholesterolemia (HoFH) revealed that initiating lipoprotein apheresis in childhood, compared to pharmacotherapy, improves plasma LDL-C level and reduces cardiovascular death.Comment: Homozygous familial hypercholesterolaemia (HoFH) is a rare inherited disorder, which results in extremely elevated low-density lipoprotein cholesterol (LDL-C) levels and premature atheros...

ey0021.12-16 | Lipid Metabolism | ESPEYB21

12.16. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia

A Wiegman , S Greber-Platzer , S Ali , MD Reijman , EA Brinton , MJ Charng , S Srinivasan , C Baker-Smith , S Baum , JA Brothers , J Hartz , PM Moriarty , J Mendell , S Bihorel , P Banerjee , RT George , B Hirshberg , R Pordy

Homozygous familial hypercholesterolemia (HoFH) is a severe disorder caused by genetic mutations in LDLR (encoding the LDL receptor), APOB or PCSK9. LDL-C levels in HoFH are extremely elevated)>400 mg/dL(even in utero, leading to cardiovascular events, and disability or death during childhood and adolescence. Conventional medications have minimal efficacy, since LDL-C levels cannot be reduced through upregulation of hepatic LDL receptors.<p c...